Literature DB >> 24643640

Cardiovascular oncology: a new discipline inside internal medicine?

Domenico Prisco1, Mario Milco D'Elios, Caterina Cenci, Lucia Ciucciarelli, Carlo Tamburini.   

Abstract

Cardiovascular disease and cancer incidence and prevalence have risen over the past few decades to become the leading causes of death. On the one hand, cancer patients will be treated with cardiotoxic chemotherapies; on the other, cardiovascular patients will receive a new diagnosis of cancer and will have to face treatments that may worsen their disease. Moreover, venous thromboembolism can commonly complicate the natural course of patients with cancer in an apparently spontaneous manner or can be triggered by a clinical event such as surgery, invasive procedures, a course of chemotherapy or radiotherapy and is known to be the second cause of death in these patients who also may need to be treated for pre-existing medical conditions or comorbidities. Thus, we introduce the concept of cardiovascular oncology (in the place of cardiooncology) to underline that the problems in this field are not limited to cardiotoxicity of chemotherapies and to the interaction between cardiologists and oncologists, and we focus on the role of the Internist, the only health care giver able to face the multiple problems that cancer patients may undergo.

Entities:  

Mesh:

Year:  2014        PMID: 24643640     DOI: 10.1007/s11739-014-1064-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  23 in total

Review 1.  Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Intern Emerg Med       Date:  2011-12-13       Impact factor: 3.397

2.  Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

Authors:  M Mandalà; A Falanga; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 3.  Cancer-associated thrombosis: updates and controversies.

Authors:  Alok A Khorana
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

4.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Authors:  G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

Review 6.  Cancer drugs and the heart: importance and management.

Authors:  Thomas M Suter; Michael S Ewer
Journal:  Eur Heart J       Date:  2012-07-12       Impact factor: 29.983

7.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

8.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 9.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Authors:  D Farge; P Debourdeau; M Beckers; C Baglin; R M Bauersachs; B Brenner; D Brilhante; A Falanga; G T Gerotzafias; N Haim; A K Kakkar; A A Khorana; R Lecumberri; M Mandala; M Marty; M Monreal; S A Mousa; S Noble; I Pabinger; P Prandoni; M H Prins; M H Qari; M B Streiff; K Syrigos; H Bounameaux; H R Büller
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316

View more
  5 in total

1.  ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.

Authors:  Emanuel Raschi; Igor Diemberger; Benilde Cosmi; Fabrizio De Ponti
Journal:  Intern Emerg Med       Date:  2017-09-23       Impact factor: 3.397

2.  Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer.

Authors:  Gregory T Armstrong; Jordan D Ross
Journal:  Prog Pediatr Cardiol       Date:  2014-09-01

3.  A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

Authors:  Alice C O'Farrell; Rhys Evans; Johanna M U Silvola; Ian S Miller; Emer Conroy; Suzanne Hector; Maurice Cary; David W Murray; Monika A Jarzabek; Ashwini Maratha; Marina Alamanou; Girish Mallya Udupi; Liam Shiels; Celine Pallaud; Antti Saraste; Heidi Liljenbäck; Matti Jauhiainen; Vesa Oikonen; Axel Ducret; Paul Cutler; Fionnuala M McAuliffe; Jacques A Rousseau; Roger Lecomte; Suzanne Gascon; Zoltan Arany; Bonnie Ky; Thomas Force; Juhani Knuuti; William M Gallagher; Anne Roivainen; Annette T Byrne
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

4.  Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.

Authors:  Ella Grilz; Oliver Königsbrügge; Florian Posch; Manuela Schmidinger; Robert Pirker; Irene M Lang; Ingrid Pabinger; Cihan Ay
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

5.  Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer.

Authors:  Ella Grilz; Christine Marosi; Oliver Königsbrügge; Julia Riedl; Florian Posch; Wolfgang Lamm; Irene M Lang; Ingrid Pabinger; Cihan Ay
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.